Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06596252 · ClinicalTrials.gov registry record · Phase 3
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
A Phase 3 study of Eosinophilic Esophagitis, sponsored by Dr. Falk Pharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 308
- Enrollment target
- 20
- Study locations
NCT06596252 is a Phase 3 study of Eosinophilic Esophagitis that is actively recruiting participants, run by Dr. Falk Pharma. The registered enrollment target is 308 participants, below the 857-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT06596252, a Phase 3 study of Eosinophilic Esophagitis, is actively recruiting participants, sponsored by Dr. Falk Pharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 308 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis.
Conditions Studied
Interventions
- DRUG Budesonide
Study Locations (20)
California
- Dr. Falk Investigational Site - La Jolla
- Dr. Falk Investigational Site - Lomita
- Dr. Falk Investigational Site - San Diego
Florida
- Dr. Falk Investigational Site - Doral
- Dr. Falk Investigational Site - New Port Richey
Louisiana
- Dr. Falk Investigational Site - Houma
- Dr. Falk Investigational Site - Marrero
Michigan
- Wyoming - Ann Arbor
- Dr. Falk Investigational Site - Wyoming
New Jersey
- Dr. Falk Investigational Site - Freehold
- Dr. Falk Investigational Site - Jackson
Ohio
- Dr. Falk Investigational Site - Cleveland
- Dr. Falk Investigational Site - Mentor
Arizona
- Dr. Falk Investigational Site - Scottsdale
Arkansas
- Dr. Falk Investigational Site - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2021-05-21 |
| Est. Completion | 2027-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06596252
The ClinicalTrials.gov registry entry for NCT06596252 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 308 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 857-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (64% lower). The listed sponsor is Dr. Falk Pharma, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 1 intervention - of which Budesonide is the first listed.
NCT06596252 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT06596252 about?
NCT06596252 is a clinical study titled "Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE". The purpose of this study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis.
What is the current status of trial NCT06596252?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 308 participants. The study started on 2021-05-21. Estimated completion is 2027-03.
What conditions does trial NCT06596252 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis.
What interventions are being tested in trial NCT06596252?
The interventions under investigation include: Budesonide (DRUG).
Who is sponsoring clinical trial NCT06596252?
This trial is sponsored by Dr. Falk Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06596252 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
ACTIVE NOT RECRUITING · Phase 3
-
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
COMPLETED · Phase 3
-
Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)
COMPLETED · Phase 3
-
Characteristics and Inflammatory Markers in Children with Eosinophilic Esophagitis (EoE)
RECRUITING
-
Changes in Esophageal Distensibility With Proton Pump Inhibitors in Patients With Esophageal Eosinophilia: A Pilot Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.